Application of CRISPR/Cas9 gene-editing technology in Alzheimers disease

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder. It triggers metabolic disorders within the body due to genetic mutations, thus leading to irreversible damage to one's memory and brain. The primary pathogenic features of AD are intracellular neurofibrillary tangles caused by hyperphosphorylated Tau and extracellular amyloid plaques created by the buildup of -amyloid -protein (A). However, up to now, there has been no effective treatment program for Alzheimer's disease. And after a long time of development, many gene editing technologies have been perfected and utilized in practice. Among them, CRISPR-Cas9 technology is the most efficient and practical. As a result, an increasing number of scientists have examined and debated the potential use of CRISPR-Cas9 technology in the management of Alzheimer's disease. This review addresses the use of the CRISPR/Cas9 system to treat Alzheimer's disease and presents the disease's pathophysiology, including the establishment of AD models, genetic screening for the cause of AD, and targeted therapy for AD.